Treatment of cryptorchidism by intranasal synthetic luteinising-hormone releasing hormone. Results of a collaborative double-blind study
Illig, R.; Exner, G.U.; Kollmann, F.; Kellerer, K.; Borkenstein, M.; Lunglmayr, L.; Kuber, W.; Prader, A.
Lancet 2(8037): 518-520
1977
ISSN/ISBN: 0140-6736 PMID: 95729 Document Number: 116343
The effect of intranasal luteinizing-hormone releasing hormone (LHRH.) in 84 boys with unilateral or bilateral cryptorchidism was evaluated in a double-blind controlled trial. Boys with retractile testes were not studied. LHRH caused no side-effects; plasma antibodies to LHRH were never demonstrated. Therapy with intranasal LHRH for 4 wk administered in 6 doses daily (1.2 mg/day) led to complete descent in 38% of a total of 61 testes, an improved position in 28% and no response in 19%; 15% of testes were never palpated. After placebo the position of 25% of testes was improved; there was no response in 75% of a total of 51 testes. The success-rate seemed to be independent of age, but was related to the initial testicular position, with complete descent in only 1 of testes not previously palpated compared with 48% of testes found in the inguinal region.